TruScreen Group (TRU) investor relations material

Executive summary

• Product sales for the first half of FY2026 reached NZ$860k, with full-year revenue guidance maintained at NZ$2.8m.

• China remains the strongest market, while new public screening programs in Zimbabwe and Vietnam are set to begin in 2H FY2026.

• Strategic alliances and new distributors in India and South Africa expand market reach.

• A successful capital raise of NZ$4m is expected to support the company to monthly cash flow positivity by late FY2026.

• Ms Christine Pears joined the Board, replacing Ms Juliet Hull.

Financial highlights

• Revenue from product sales decreased 17% year-over-year to NZ$860,795 due to deferred programs.

• Operating loss increased to NZ$1.36m (1H FY2025: NZ$1.13m), including capital raise costs.

• Net operating cash outflow rose to NZ$1.7m (1H FY2025: NZ$0.9m), impacted by lower receipts and higher prepayments.

• Cash and cash equivalents at 30 September 2025 were NZ$2.2m.

• Basic and diluted loss per share was (0.19) cents (1H FY2025: (0.21) cents).

Outlook and guidance

• FY2026 revenue guidance affirmed at NZ$2.8m, with 2H FY2026 expected to reflect deferred sales and new program launches.

• Public screening programs are projected to contribute 20% of annual revenue.

• Company expects to achieve monthly positive cash flow by late FY2026.